131 related articles for article (PubMed ID: 15843678)
1. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
Behrens GM
N Engl J Med; 2005 Apr; 352(16):1721-2; author reply 1721-2. PubMed ID: 15843678
[No Abstract] [Full Text] [Related]
2. Treating antiretroviral-induced dyslipidemia in HIV-infected adults.
Scordo KA
Nurse Pract; 2010 Jul; 35(7):32-7; quiz 37-8. PubMed ID: 20555242
[No Abstract] [Full Text] [Related]
3. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
Grinspoon S; Carr A
N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
[No Abstract] [Full Text] [Related]
4. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
Manuel DG; Tanuseputro P; Mustard CA; Schultz SE; Anderson GM; Ardal S; Alter DA; Laupacis A
CMAJ; 2005 Apr; 172(8):1027-31. PubMed ID: 15824409
[No Abstract] [Full Text] [Related]
5. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
[TBL] [Abstract][Full Text] [Related]
6. Lipid lowering therapy for adults with diabetes.
Jackowski L; Crockett J; Rowett D
Aust Fam Physician; 2008; 37(1-2):39-41. PubMed ID: 18239751
[TBL] [Abstract][Full Text] [Related]
7. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Martínez E; Tuset M; Milinkovic A; Miró JM; Gatell JM
Antivir Ther; 2004 Oct; 9(5):649-63. PubMed ID: 15535403
[TBL] [Abstract][Full Text] [Related]
8. [What other effects do statins have except their effect on lipids?].
Tikkanen MJ
Duodecim; 1998; 114(13):1299-301. PubMed ID: 11552256
[No Abstract] [Full Text] [Related]
9. Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.
Aberg JA
Top HIV Med; 2006; 14(4):134-9. PubMed ID: 17114827
[TBL] [Abstract][Full Text] [Related]
10. Coronary heart disease in HIV-infected persons.
Glesby MJ
AIDS Read; 2003 Apr; 13(4 Suppl):S15-9. PubMed ID: 12762289
[TBL] [Abstract][Full Text] [Related]
11. Complications and side effects. Crestor tested in PHAs.
TreatmentUpdate; 2005; 17(4):6-7. PubMed ID: 17230630
[No Abstract] [Full Text] [Related]
12. Lipid-lowering drugs and changes to diet can make a difference.
TreatmentUpdate; 2001 Aug; 13(4):7-9. PubMed ID: 11590981
[No Abstract] [Full Text] [Related]
13. Complications and side effects. Concerns about statins.
TreatmentUpdate; 2005; 17(4):5-6. PubMed ID: 17228472
[No Abstract] [Full Text] [Related]
14. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.
Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F;
HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977
[TBL] [Abstract][Full Text] [Related]
15. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease.
Ferdinand KC
Curr Med Res Opin; 2005 Jul; 21(7):1091-7. PubMed ID: 16004678
[TBL] [Abstract][Full Text] [Related]
16. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
Dubé MP; Sprecher D; Henry WK; Aberg JA; Torriani FJ; Hodis HN; Schouten J; Levin J; Myers G; Zackin R; Nevin T; Currier JS;
Clin Infect Dis; 2000 Nov; 31(5):1216-24. PubMed ID: 11073755
[TBL] [Abstract][Full Text] [Related]
17. Dyslipidaemia in diabetes--a GP guide.
Barnett AH
Practitioner; 2002 Feb; 246(1631):120-3. PubMed ID: 11852620
[No Abstract] [Full Text] [Related]
18. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL
Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061
[TBL] [Abstract][Full Text] [Related]
19. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
Sherrod JP; Krist A
J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
[No Abstract] [Full Text] [Related]
20. Improvement in current approaches to lipid lowering.
Ansell BJ
Am Fam Physician; 2002 Mar; 65(5):783, 786-7. PubMed ID: 11898952
[No Abstract] [Full Text] [Related]
[Next] [New Search]
